This report organizes information from diverse sources into sections such as an overview, industry structure, diagnostic test type, treatment by drug categories, leading drug profiles and historic drug sales, regulations, reimbursements, and patents. The scope of this report includes an overview of the global market scenario for the diagnosis and treatment of HIV, with base year data from 2022, estimations for 2023 and forecasts for 2028 that are derived using projections of CAGR during the forecast period. Market value data is provided at global, regional, and country levels for treatments by drug categories. Market data for HIV diagnostics is provided for regional levels, with details on test types. Estimated values are based on companies’ total revenues. Projected and forecasted revenue values are in constant U.S. dollars that have not been adjusted for inflation.
The report forecasts the global market for HIV therapeutics by drug class. It discusses market data for nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs), protease inhibitors (PIs), single tablet regimen fixed-dose combination (STR FDC), HIV integrase strand transfer inhibitors (INSTIs) and non-nucleoside reverse transcriptase inhibitors (NNRTIs). The enzyme inhibitor drug class has been excluded when calculating the global HIV therapeutics market, as there are no late-stage pipeline molecules.
Diagnostic tests such as antigen-and antibody-based tests, CD4 tests and viral load tests are detailed with current and forecasted market data. Antigen-and antibody-based tests cover enzyme-linked immunosorbent assay (ELISA) tests, enzyme immunoassay (EIA) tests, rapid tests, and NAT tests; CD4 tests include tests conducted to monitor the CD4 load; and viral load tests include all PCR-based tests.
A detailed analysis illustrating market dynamics and market structure is incorporated into the report. A Porter’s Five Forces analysis and the supply and distribution chain are discussed in detail to provide an in-depth understanding of this market. The report covers the current regulations and guidelines for diagnostics and therapeutics for HIV, and it provides a survey of the top market players, detailing their business operations, segment focus, revenue, and strategy analysis. The report also features a market share analysis of these leading players, including information about product launches and pipeline products.
In terms of geography, the report analyzes the market across the following regions: North America, Europe, Asia-Pacific and Rest of the World (RoW). Key countries like the U.S., Canada, Mexico, Germany, France, UK, Italy, China, India and Japan are given special focus due to the high concentration of HIV diagnostics and therapeutics manufacturing companies and contract manufacturing organizations located in these areas.
The base year for the market data in this report is 2022, historical data is provided for 2020 and forecast data is given for 2028. Historical, base year and forecast data are provided for each market segment of the report.
Report Includes
- 27 data tables and 41 additional tables
- An overview of the global markets for diagnostics and therapeutics for HIV
- An estimate of the market’s size and analyses of global market trends, with data from 2020-2022, estimates for 2023, and projections of compound annual growth rates (CAGRs) through 2028
- Quantification of the market potential of diagnostics and therapeutics for HIV by drug category, diagnostic test type, and region
- Coverage of HIV timeline and milestones, HIV life cycle, its treatment and mechanism of action, and description of HIV prophylaxis
- Evaluation of market dynamics such as drivers and restraints, current industry trends and patterns, and an assessment of the cost implications for treatments in many countries
- Information on regional awareness programs, WHO initiatives and development of novel therapies, and discussion on rising comorbidities in HIV patients and social stigma associated with STDs
- Coverage of ongoing research and predictions of the market’s future direction
- Insights into the regulatory scenario for the U.S., Europe and Japan, to provide an overview of the regulations for new drug launches and diagnostic kits
- Descriptions of the competitive landscape, product mapping, the strategic initiatives of the leading companies, including their R&D activities
- Profiles of the key companies, including Medtronic, Abbott, Sanofi, Roche, Bio-Rad Laboratories Inc., and Danaher Corp.
Table of Contents
Executive Summary
In 2019, around 38 million people worldwide were HIV-positive. About 20.7 million of those infected with HIV lived in Eastern and Southern Africa. Of the 25 countries with the highest prevalence of HIV in 2019, all were in Africa. HIV prevalence in North America and Europe is significantly lower than in other regions, attributed to better awareness, higher hygiene standards and better HIV prevention.
After a peak in 2004-2005, the number of AIDS deaths has steadily declined Still, there were approximately 690,000 AIDS-related deaths worldwide in 2019, with most of them again occurring in Sub-Saharan Africa. South Africa had the highest number of deaths due to AIDS, with around 72,000 in 2019. Among countries outside Africa, India has the highest number of AIDS-related deaths.
Effective antiretroviral treatment is available to manage HIV/AIDS, and treatment coverage has been extended to developing nations. In the absence of an effective treatment that cures the disease, governments rely on HIV diagnostics and prevention methods to slow the spread of this epidemic.
HIV is transmitted through the exchange of body fluids, which can occur through sexual encounters and the use of contaminated blood or blood products. It can also be transmitted from a pregnant woman to her infant during pregnancy, delivery or breastfeeding. It has additionally been reported that transmission can occur from organ transplants if the donor is HIV-positive. HIV is highly divergent, and several subtypes exist globally. The two major HIV subtypes are HIV-1 and HIV-2. HIV testing is conducted to ensure the safety of blood, blood products, organ transplantation and patient diagnosis.
For effective HIV management, the key strategies are early diagnosis, rapid antiretroviral therapy (ART) initiation and viral load monitoring. A vital issue with existing HIV therapies is that they fail to address two rising concerns: the long-term adverse effects of therapeutic drugs and their effectiveness against drug-resistant HIV strains.
The global market for diagnostics and therapeutics for HIV was valued at $28.8 billion in 2022. This market is forecast to grow at a compound annual growth rate (CAGR) of 5.3% to reach $39.3 billion in 2028.
The single-tablet regimen FDC segment holds 37.2% of the market share of the global HIV therapeutics market, as this has become the preferred therapy for HIV treatment due to greater patient compliance. As fixed-dose combinations reduce dosing errors and lower the likelihood of the HIV virus becoming drug resistant, they are increasingly preferred. By 2028, NRTIs will hold 29.0% of the global market, a $11.0 billion value, as they form the backbone of any antiretroviral therapy.
Companies Mentioned
- Abbott
- Astrazeneca
- B. Braun Se
- Becton, Dickinson and Company
- Biocon
- Bio-Rad Laboratories Inc.
- Boehringer Ingelheim International GmbH
- Danaher Corp.
- Dexcom Inc.
- Insulet Corp.
- Johnson & Johnson Services Inc.
- Lifescan Ip Holdings LLC
- Lilly
- Medtronic
- Merck & Co. Inc.
- Nova Biomedical
- Novartis AG
- Novo Nordisk A/S
- Qiagen N.V.
- Roche (F. Hoffmann-La Roche Ltd.)
- Sanofi
- Siemens Healthineers AG
- Terumo Corp.
- Thermo Fisher Scientific Inc.
- Ypsomed Ag
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 186 |
| Published | October 2023 |
| Forecast Period | 2023 - 2028 |
| Estimated Market Value ( USD | $ 30.4 Billion |
| Forecasted Market Value ( USD | $ 39.3 Billion |
| Compound Annual Growth Rate | 5.3% |
| Regions Covered | Global |
| No. of Companies Mentioned | 25 |
